Study ID | Sample size | Age | Sex M/F | Comparisons | Outcome | Follow up |
---|---|---|---|---|---|---|
CAM vs usual care, 3 studies | ||||||
Liu CH 2009 [20] | T:150 C:148 | T:1-6 m, 80 cases; 6-12 m, 50 cases; 1-2 y, 20 cases C:1-6 m, 83 cases; 6-12 m, 44 cases; 1-2 y, 21 cases | T:88/62 C:86/44 | Swimming therapy + Baibu (Stemona japonica) lotion (bath) + Tuina vs Cyproheptadine (oral) + Boric lotion (external application with cold lotion)/Hydrocortisone butyrate cream (external use)/Zinc oxide cream (external use) (7-15d) | Improvement of symptoms and signs and signs; IgG; Relapse (T:26/150, 3 m; 37/150, 6 m C:80/148, 3 m; 96/148, 6 m) | 3 m, 6 m |
Liu WQ 2016 [21] | T:60 C:60 | T:(4.5 ± 3.8) y C:(5.3 ± 4.5) y | T:37/23 C:33/27 | Fasting and rotation diet vs Pevisone paste (external use) (3 m) | Improvement of symptoms and signs; IgG; Relapse (T:4/60 C:11/60) | 3 m |
Wu YQ 2014 [22] | T:74 C:74 | T:(6.35 ± 1.36) m C:(5.98 ± 1.23) m | T:41/33 C:31/43 | Velvetfeeling lotion (external application) + Moisturizing cream (external use) + Saline water (dipping) vs Boric lotion (external application) + Vitamin E (external use) + Saline water (dipping) (7d) | Improvement of symptoms and signs; CGI-EI | NR |
CAM + usual care vs usual care, 10 studies | ||||||
Chen DX 2015 [23] | T:20 C:20 | T:(3.82 ± 0.7) m C:(2.35 ± 1.3) m | NR | Bifid triple viable capsules (oral) + Hydrocortisone butyrate cream (external use) vs Hydrocortisone butyrate cream (external use) (180d) | Improvement of symptoms and signs | 6 m |
Chen YL 2015 [24] | T:58 C:58 | T:(11 ± 5) m C:(12 ± 5) m | T:31/27 C:30/28 | Probiotics (oral) + Chlorphenamine maleate tablets (oral) + Vitamin B6 + Fluocinonide cream (external use) + Calcium supplement (oral) vs Chlorphenamine maleate tablets (oral) + Vitamin B6 + Fluocinonide Cream (external use) + Calcium supplement (oral) (28d) | Improvement of symptoms and signs; CGI-EI; Interleukin; Interferon; Relapse (T:9/58 C:29/58) | NR |
Guo YH 2015 [25] | T:90 C:90 | T:2 m-3 y C:2 m-3 y | total: 98/82 | Tetralogy of viable bifidobacterium tablets (oral) + Usual care (Calamine lotion/ Zinc oxide cream/ Loratadine syrup/ Mometasone furoate cream) vs Usual care (Calamine lotion/Zinc oxide cream/Loratadine syrup/Mometasone furoate cream) (30d) | Improvement of symptoms and signs; IL-4, IL-10, IFN-γ, IgE, Th1/Th2; Relapse (T:24/90 C:62/90) | 3 m |
Jiang YX 2013 [26] | T:65 C:60 | T:2 y C:2 y | total: 72/53 | Velvetfeeling lotion (external application) + Usual care (eg. Chlorphenamine maleate tablets) vs Usual care (eg. Chlorphenamine maleate tablets) + Boric lotion (external application) (28d) | Improvement of symptoms and signs | NR |
Li DY 2012 [27] | T:32 C:30 | T:(7.15 ± 2.06) m C:(6.89 ± 2.54) m | T:17/15 C:16/14 | Bifid triple viable capsules (oral) + Zinc oxide cream (external use) + Boric lotion (external application) vs Zinc oxide cream (external use) + Boric lotion (external application) (14d drugs for external use/28d Oral bifid-triple viable capsule) | Improvement of symptoms and signs; Relapse (T:6/32 C:20/30) | NR |
Mao HX 2013 [28] | T:50 C:50 | T:2 m-5 y C:2 m-5 y | T:24/26 C:28/22 | Probiotics (oral) + Antihistamines (oral) + Calcium supplement (oral) + Skincare cream (external use) vs Antihistamines (oral) + Calcium supplement (oral) + Skincare cream (external use) | Improvement of symptoms and signs; Relapse (T:2/50 C:12/50) | NR |
Wei MX 2010 [29] | T:38 C:36 | T:(6.78 ± 2.62) m C:(7.14 ± 2.10) m | T:22/16 C:19/17 | Viable Bacillus coagulans tablets (oral) + Boric lotion (wash-out) + Zinc oxide cream (external use) vs Boric lotion (wash-out) + Zinc oxide cream (external use) (28d) | Improvement of symptoms and signs; Relapse (T:7/38 C:24/36) | 6 m |
Ye CQ 2017 [30] | T:48 C:48 | T:(6.9 ± 2.4) m C:(6.8 ± 2.6) m | T:27/21 C:28/20 | Condensation living bacterium bacillus (oral) + Boric lotion (wash-out) + Zinc oxide cream (external use) vs Boric lotion (wash-out) + Zinc oxide cream (external use) (28d) | Improvement of symptoms and signs; Relapse (T:6/48 C:28/48) | 6 m |
Zhang MH 2013 [31] | T:35 C:35 | T:(5 ± 3) m C:(6 ± 3) m | T:27/8 C:25/10 | Bifico lriple viable (oral) + Boric lotion (wash-out) + Zinc oxide cream (external use) + Cetirizine hydrochloride drops (oral) vs Boric lotion (wash-out) + Zinc oxide cream (external use) + Cetirizine hydrochloride drops (oral) (30d) | IFN-γ; Interleukin; T-Cell; Relapse (T:6/35 C:16/58) | 6 m |
Zhang XN 2013 [32] | T:36 C:34 | total:(7.06 ± 3.48) y | total:32/38 | Velvetfeeling lotion (external application) + Butyl flufenamate ointment (external use) + Antihistamine (oral) vs Saline water (external application) + Butyl flufenamate ointment (external use) + Antihistamine (oral) (14d) | Improvement of symptoms and signs; CGI-EI | NR |
CAM vs placebo, 9 studies | ||||||
D. Sistek 2006 [33] | T:30 C:29 | T:3.8 y C:4.4 y | T:15/14 C:17/13 | Probiotics (oral) vs Placebo (oral) (12w) | Improvement of symptoms and signs | 4w |
Hyeon-Jong Yang 2014 [34] | T:50 C:50 | T:(58.7 ± 29.9) m C:(47.4 ± 28.1) m | T:29/21 C:24/26 | Probiotics (oral) vs Placebo (oral) (6w) | Improvement of symptoms and signs; Fecal cell counts; IL-4; TNF-α | NR |
Reza 2011 [35] | T:19 C:21 | T:(28.68 ± 40.86) m C:(22.76 ± 34.03) m | T:11/8 C:14/7 | Synbiotic (oral) vs Placebo (oral) (8w) | Improvement of symptoms and signs Mononuclear cells | NR |
S Weston 2017 [36] | T:28 C:28 | T:(11.5 ± 4.2) m C:(10.3 ± 3.2) m | T:14/14 C:16/12 | VRI-003 PCC freeze dried powder probiotics (oral) vs Placebo (oral) (8w) | Improvement of symptoms and signs; total IgE levels; radioallergosorbent test | 8w |
Sergei V. Gerasimov 2010 [37] | T:48 C:48 | T:(25.6 ± 7.7) m C:(24.1 ± 6.3) m | T:28/15 after withdrew C:28/19 after withdrew | Probiotics (oral) vs Placebo (oral) (8w) | Improvement of symptoms and signs; Quality of life; Total IgE; Eosinophil count | NR |
Shoko 2007 [38] | T:16 C:16 | T:4.44 y C:5.56 y | T:9/7 C:12/4 | Borage oil (undershirts coated with oil) vs Placebo (non-coated undershirts) (2w) | Improvement of symptoms and signs; Changes of transepidermal water loss | NR |
Wu YJ 2017 [39] | T:33 C:33 | T:(1.5 ± 1.1) m C:(7.14 ± 2.10) m | T:25/8 C:19/14 | Probiotics (Lactobacillus rhamnosus) (oral) vs Placebo (oral) (8w) | Improvement of symptoms and signs; Quality of Life (Infant Dermatitis Quality of Life Questionnaires and Dermatitis Family Impact Questionnaires); | NR |
Yavuz 2012 [40] | T:20 C:20 | total:1-13 y | total: 23/17 | Probiotic bacteria (oral) vs Placebo (oral) (8w) | Improvement of symptoms and signs; cytokine analyse/IgE/Eosinophil cationic protein | 10w |
Youngshin 2012 [41] | T:58 C:60 | T:(4.6 ± 3.3) y C:(5.1 ± 3.3) y | T:34/24 C:35/25 | Probiotics (L. plantarum CJLP133) (oral) vs Placebo (oral) (12w) | Improvement of symptoms and signs; total IgE levels/specific IgE | 2w |
Multi-armed trials, 2 studies | ||||||
Pasi E. Kankaanpa 2002 [42] | T1:5 T2:5 C1:5 | T1:(4.5 ± 2) m T2:(5.7 ± 2.2) m C1:(5.6 ± 2.1) m | T1:2/3 T2:3/2 C1:2/3 | Probiotics (Lactobacillus GG) (oral) vs Probiotics (Bifidobacterium Bb12) (oral) vs placebo (oral) (①4.4 ± 1.7 m ②7.3 ± 0.7 m ③5.7 ± 2.0 m) | Fatty acid analysis | ≥36 m follow until panticipants at the age of 3 years |
C. Gore 2011 [43] | T1:45 T2:45 C1:47 C2:22 C3:49 | T1:19 [16-23] w T2:20.5 [17-23] w C1:20 [16-23] w C2:15 [13-19.5] w C3:19 [15-21.5] w | T1:28/17 T2:24/21 C1:28/19 C2:16/6 C3:25/24 | Probiotics (Lactobacillus paracasei) (oral) vs Probiotics (Bifidobacterium) (oral) vs Placebo (oral) vs Exclusively breastfed vs Standard formula-fed (12w) | Improvement of symptoms and signs; Quality of life; Stool; GI-Permeability; Specific serum IgE; Urinary EPX | NR |